By Traci Hacker

Beckman Coulter, a global clinical diagnostics leader, will introduce new antipsychotic drug tests to laboratories and health care professionals.  The tests measure blood levels of antipsychotic drugs for people taking them to treat schizophrenia or bipolar disorder. The goal is to help health care professionals evaluate consumer treatment adherence and individual consumer drug response. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests. These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor the following antipsychotics: clozapine, risperidone/paliperidone, olanzapine, quetiapine, and aripiprazole. The rapid, high-quality assays run…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!